Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NZV930 +/- spartalizumab +/- taminadenant in advanced malignancies
NCT03549000Phase 1Terminated
- Sponsor
- Novartis
- Start
- Jul 2018
- Primary completion
- Oct 2022
- Modality
- Prophylactic Vaccines, IgG Antibodies, Therapeutic Vaccines
- Countries
- 7
01
Overview
Phase 1, open-label trial of NZV930 in non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), pancreatic ductal adenocarcinoma (PDAC) and 4 more (4 arms), sponsored by Novartis. Primary endpoint: Number of participants with adverse events at 3 years. Started Jul 2018; status: terminated.
02
Drugs
NZV930
03
Conditions
non-small cell lung cancer (NSCLC)triple-negative breast cancer (TNBC)pancreatic ductal adenocarcinoma (PDAC)colorectal cancer (CRC)ovarian cancer
Beyond the preview
Go deeper on NCT03549000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03549000.